The indigenous COVID-19 vaccine, Covaxin, has an efficacy of 77.8% against symptomatic COVID-19 and has been found to be 65.2% effective against the Delta (B.1.617.2) variant, said the vaccine developer, Bharat Biotech.

The vaccine is 93.4% effective against severe symptomatic infection and is 63.6% protective against asymptomatic infection, said the company as it revealed the final results of the phase III trials that included 25,800 participants aged 18 to 98 years. Additionally, Covaxin appears to have a 79.4% efficacy among those aged below 60 in comparison with 67.8% efficacy among individuals aged 60 years and above. The results are published in the preprint server MedRxiv… (ET Healthworld – TNN, July 4, 2021)